251 related articles for article (PubMed ID: 17591019)
1. Normalization of fat accrual in lipoatrophic, HIV-infected children switched from stavudine to tenofovir and from protease inhibitor to efavirenz.
Viganò A; Brambilla P; Cafarelli L; Giacomet V; Borgonovo S; Zamproni I; Zuccotti G; Mora S
Antivir Ther; 2007; 12(3):297-302. PubMed ID: 17591019
[TBL] [Abstract][Full Text] [Related]
2. Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children.
Viganò A; Aldrovandi GM; Giacomet V; Merlo M; Martelli L; Beretta S; Luraschi P; Rombolà G; Mora S
Antivir Ther; 2005; 10(8):917-24. PubMed ID: 16430197
[TBL] [Abstract][Full Text] [Related]
3. Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study).
Ribera E; Paradiñeiro JC; Curran A; Sauleda S; García-Arumí E; Castella E; Puiggròs C; Crespo M; Feijoo M; Diaz M; Del Saz SV; Planas M; Sureda D; Falcó V; Ocaña I; Pahissa A
HIV Clin Trials; 2008; 9(6):407-17. PubMed ID: 19203906
[TBL] [Abstract][Full Text] [Related]
4. Effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus-related fat redistribution evaluated by dual-energy x-ray absorptiometry.
Tavassoli N; Bagheri H; Sommet A; Delpierre C; Marion-Latard F; Massip P; Aquilina C; Bonnet E; Obadia M; Labau E; Montastruc JL; Bernard J
Pharmacotherapy; 2006 Feb; 26(2):154-61. PubMed ID: 16466321
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.
Gallant JE; Staszewski S; Pozniak AL; DeJesus E; Suleiman JM; Miller MD; Coakley DF; Lu B; Toole JJ; Cheng AK;
JAMA; 2004 Jul; 292(2):191-201. PubMed ID: 15249568
[TBL] [Abstract][Full Text] [Related]
6. Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial.
Valantin MA; Lanoy E; Bentata M; Kalmykova O; Boutekadjirt A; Allavena C; Rozenbaum W; Peytavin G; Amellal B; Calvez V; Costagliola D; Katlama C;
HIV Med; 2008 Oct; 9(8):625-35. PubMed ID: 18624724
[TBL] [Abstract][Full Text] [Related]
7. The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in hiv-1-infected patients: three-year follow-up after switching therapy.
Madruga JR; Cassetti I; Suleiman JM; Etzel A; Zhong L; Holmes CB; Cheng AK; Enejosa J;
HIV Clin Trials; 2007; 8(6):381-90. PubMed ID: 18042503
[TBL] [Abstract][Full Text] [Related]
8. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients.
John M; McKinnon EJ; James IR; Nolan DA; Herrmann SE; Moore CB; White AJ; Mallal SA
J Acquir Immune Defic Syndr; 2003 May; 33(1):29-33. PubMed ID: 12792352
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen.
Gerschenson M; Kim C; Berzins B; Taiwo B; Libutti DE; Choi J; Chen D; Weinstein J; Shore J; da Silva B; Belsey E; McComsey GA; Murphy RL
J Antimicrob Chemother; 2009 Jun; 63(6):1244-50. PubMed ID: 19321503
[TBL] [Abstract][Full Text] [Related]
10. Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine.
Havlir DV; Koelsch KK; Strain MC; Margot N; Lu B; Ignacio CC; Miller MD; Wong JK;
J Infect Dis; 2005 Apr; 191(7):1164-8. PubMed ID: 15747253
[TBL] [Abstract][Full Text] [Related]
11. Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384.
Dubé MP; Komarow L; Mulligan K; Grinspoon SK; Parker RA; Robbins GK; Roubenoff R; Tebas P;
J Acquir Immune Defic Syndr; 2007 Aug; 45(5):508-14. PubMed ID: 17589373
[TBL] [Abstract][Full Text] [Related]
12. Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: final results of the EFADITE trial.
Barrios A; Negredo E; Domingo P; Estrada V; Labarga P; Asensi V; Morales D; Santos J; Clotet B; Soriano V;
Antivir Ther; 2005; 10(7):825-32. PubMed ID: 16312178
[TBL] [Abstract][Full Text] [Related]
13. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study.
McComsey GA; Ward DJ; Hessenthaler SM; Sension MG; Shalit P; Lonergan JT; Fisher RL; Williams VC; Hernandez JE;
Clin Infect Dis; 2004 Jan; 38(2):263-70. PubMed ID: 14699460
[TBL] [Abstract][Full Text] [Related]
14. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients.
Milinkovic A; Martinez E; López S; de Lazzari E; Miró O; Vidal S; Blanco JL; Garrabou G; Laguno M; Arnaiz JA; Leon A; Larrousse M; Lonca M; Mallolas J; Gatell JM
Antivir Ther; 2007; 12(3):407-15. PubMed ID: 17591031
[TBL] [Abstract][Full Text] [Related]
15. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression.
Gulick RM; Lalama CM; Ribaudo HJ; Shikuma CM; Schackman BR; Schouten J; Squires KE; Koletar SL; Pilcher CD; Reichman RC; Klingman KL; Kuritzkes DR
AIDS; 2007 Apr; 21(7):813-23. PubMed ID: 17415036
[TBL] [Abstract][Full Text] [Related]
16. Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: the RECOMB study.
Ribera E; Larrousse M; Curran A; Negredo E; Clotet B; Estrada V; Sanz J; Berenguer J; Rubio R; Pulido F; Ferrer P; Alvarez ML; Arterburn S; Martínez E
HIV Med; 2013 Jul; 14(6):327-36. PubMed ID: 23298339
[TBL] [Abstract][Full Text] [Related]
17. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.
Rockstroh JK; Lennox JL; Dejesus E; Saag MS; Lazzarin A; Wan H; Walker ML; Xu X; Zhao J; Teppler H; Dinubile MJ; Rodgers AJ; Nguyen BY; Leavitt R; Sklar P;
Clin Infect Dis; 2011 Oct; 53(8):807-16. PubMed ID: 21921224
[TBL] [Abstract][Full Text] [Related]
18. Improvements in cheek volume in lipoatrophic individuals switching away from thymidine nucleoside reverse transcriptase inhibitors.
Benn P; Sauret-Jackson V; Cartledge J; Ruff C; Sabin CA; Moyle G; Linney A; Reilly G; Edwards SG
HIV Med; 2009 Jul; 10(6):351-5. PubMed ID: 19490181
[TBL] [Abstract][Full Text] [Related]
19. [To evaluate the changes in body composition in male human immunodeficiency virus-related lipodystrophy after different treatment regimens by dual-energy X-ray absorptiometry].
Zhou X; Yu W; Li T; Guo F; Lin Q; Shao H; Tian J; Xu Y; Sun P
Zhonghua Nei Ke Za Zhi; 2014 Aug; 53(8):622-5. PubMed ID: 25376824
[TBL] [Abstract][Full Text] [Related]
20. Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+ -lymphocyte count and CD4+ -lymphocyte percentage at baseline and use of protease inhibitors and stavudine.
Arpadi SM; Cuff PA; Horlick M; Wang J; Kotler DP
J Acquir Immune Defic Syndr; 2001 May; 27(1):30-4. PubMed ID: 11404517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]